Transvaginal Posterior Levatorplasty Combined with Perineoplasty: An Effective Surgical Method for Vaginal Rejuvenation.

BACKGROUND

Gynecologic cosmetic surgery and rejuvenation surgery have become increasingly popular, with growing demand for vaginal surgery to address vaginal laxity. Follow-up data on the effectiveness of these procedures remain limited. The authors conducted a retrospective study to investigate the effects of transvaginal posterior levatorplasty combined with perineoplasty on vaginal rejuvenation.

METHODS

The study included 45 patients who underwent transvaginal posterior levatorplasty combined with perineoplasty between July of 2020 and May of 2022. Patient characteristics before operation, at baseline, and 3, 6, and 12 months postoperatively, and questionnaires on patient symptoms, quality of life, and sexual function, including the Vaginal Laxity Questionnaire and Female Sexual Function Index, were evaluated. Pelvic ultrasound imaging was performed preoperatively and 3 months postoperatively.

RESULTS

Mean vaginal capacity index and vaginal laxity scores were different at baseline and 6 and 12 months postoperatively ( P < 0.01). Female sexual function, including libido, sexual arousal, lubrication, orgasm, sexual satisfaction, and pain levels, were significantly improved (preoperative, 21.68 ± 4.15; 6 months postoperatively, 26.88 ± 2.44; 1 year postoperatively, 29.97 ± 2.10; P < 0.01). Symptoms of stress urinary incontinence and recurrent vaginitis were improved in 78.6% and 90.5% of patients, respectively. On pelvic floor ultrasound, retrovesical angle, urethral rotation angle, levator hiatus, and bladder neck distance were significantly different preoperatively and 3 months postoperatively ( P < 0.01). Overall satisfaction was 93.3% at 12 months postoperatively.

CONCLUSIONS

Transvaginal posterior levatorplasty combined with perineoplasty is effective for the improvement of patient symptoms, quality of life, sexual function, stress urinary incontinence, and postnatal constipation. Further research on the underlying mechanisms is required.

CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.